Lanicemine - AstraZeneca
Alternative Names: [14C]AZD6765; AZD-6765Latest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 31 Dec 2013 Discontinued - Phase-I for Major depressive disorder in United Kingdom (IV)
- 31 Dec 2013 Discontinued - Phase-I for Major depressive disorder in USA (PO)
- 31 Dec 2013 Discontinued - Phase-II for Major depressive disorder in Chile (IV)